Successful challenge of voriconazole in a patient with posaconazole-associated minor drug eruption: A case report.
WHAT IS KNOWN AND OBJECTIVE
Triazole antifungal-associated skin rash is rare. Data on cross-reaction triazole antifungals remain inconclusive and poorly defined. We report successful voriconazole challenge in a patient allergic to posaconazole.


CASE SUMMARY
A 38-year-old female diagnosed with acute myeloid leukaemia and receiving chemotherapy treatment in our institution developed a maculopapular rash after receiving oral posaconazole for invasive fungal infection prophylaxis. Other potential causes that may have attributed to this response, such as other drugs that the patient was taking and infections, were excluded. Voriconazole, another triazole antifungal, was successfully substituted for posaconazole.


WHAT IS NEW AND CONCLUSION
This is the first case report of a patient, with a history of posaconazole allergy, successfully challenged with voriconazole.
['Weeraphon|Benjabhorn|B|https://orcid.org/0000-0003-1921-8459', 'Vanichanan|Jakapat|J|', 'Usayaporn|Sang|S|']
D000328:Adult D000935:Antifungal Agents D003937:Diagnosis, Differential D003875:Drug Eruptions D005260:Female D006801:Humans D000072742:Invasive Fungal Infections D015470:Leukemia, Myeloid, Acute D014230:Triazoles D065819:Voriconazole
voriconazole triazole cross-reactivity antifungals posaconazole maculopapular rash hypersensitivity